The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
An Intestinal Microbiota–Farnesoid X Receptor Axis Modulates Metabolic Disease
Open accessAbstract
The gut microbiota is associated with metabolic diseases including obesity, insulin resistance and non-alcoholic fatty liver disease (NAFLD), as demonstrated by correlative studies and by transplant of microbiota from obese humans and mice into germ-free mice. Modification of the microbiota by treatment of high-fat diet (HFD)-fed mice with tempol or antibiotics resulted in decreased adverse metabolic phenotypes. This was due to lower levels of the genera Lactobacillus and decreased bile salt hydrolase (BSH) activity. The decreased BSH resulted in increased levels of tauro-β-muricholic acid (T-β-MCA), a substrate of BSH and a potent farnesoid X receptor (FXR) antagonist. Mice lacking expression of FXR in the intestine were resistant to HFD-induced obesity, insulin resistance and NAFLD thus confirming that intestinal FXR is involved in the potentiation of metabolic disease. A potent intestinal FXR antagonist glycine-β-muricholic acid (Gly-MCA) that is resistant to BSH, was developed that when administered to HFD-treated mice, mimics the effect of the altered microbiota on HFD-induced metabolic disease. Gly-MCA had similar effects on genetically obese leptin-deficient mice. The decreased in adverse metabolic phenotype by tempol, antibiotics and Gly-MCA was due to decreased serum ceramides. Mice lacking FXR in intestine also have lower serum ceramides, are metabolic fit and resistant to HFD-induced metabolic disease, and this is reversed by injection of C16:0 ceramide. In mouse ileum, due to the presence of endogenous FXR agonists produced in the liver, FXR target genes involved in ceramide synthesis are activated and when Gly-MCA is administered, they are repressed, which likely accounts for the decrease in serum ceramides. These studies reveal that ceramides produced in the ileum under control of FXR, influence metabolic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952
Human gut microbiome viewed across age and geography
Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., et al. (2012) · Nature · doi:10.1038/nature11053 · Cited by 7,815
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Diversity, stability and resilience of the human gut microbiota
Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K., & Knight, R. (2012) · Nature · doi:10.1038/nature11550 · Cited by 5,533
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
Wahlström, A., Sayin, S. I., Marschall, H.-U., & Bäckhed, F. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.005 · Cited by 2,851
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites
Wikoff, W. R., Anfora, A. T., Liu, J., Schultz, P. G., Lesley, S. A., Peters, E. C., & Siuzdak, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812874106 · Cited by 2,677
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Diet–microbiota interactions as moderators of human metabolism
Sonnenburg, J. L., & Bäckhed, F. (2016) · Nature · doi:10.1038/nature18846 · Cited by 2,257
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
The Enzymes, Regulation, and Genetics of Bile Acid Synthesis
Russell, D. W. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161712 · Cited by 2,069
Cox, L. M., Yamanishi, S., Sohn, J., Alekseyenko, A. V., Leung, J. M., Cho, I., Kim, S. G., Li, H., Gao, Z., Mahana, D., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.052 · Cited by 1,859
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Self-citationLoomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Bile acids: regulation of synthesis
Chiang, J. Y. L. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900010-jlr200 · Cited by 1,515
Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483
How informative is the mouse for human gut microbiota research?
Nguyen, T. L. A., Vieira-Silva, S., Liston, A., & Raes, J. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.017400 · Cited by 1,334
Holland, W. L., Brozinick, J. T., Wang, L.-P., Hawkins, E. D., Sargent, K. M., Liu, Y., Narra, K., Hoehn, K. L., Knotts, T. A., Siesky, A., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.01.002 · Cited by 1,232
Identification of a nuclear receptor that is activated by farnesol metabolites
Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90530-8 · Cited by 1,210
Dumas, M.-E., Barton, R. H., Toye, A., Cloarec, O., Blancher, C., Rothwell, A., Fearnside, J., Tatoud, R., Blanc, V., Lindon, J. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601056103 · Cited by 1,042
Brown and Beige Fat: Physiological Roles beyond Heat Generation
Kajimura, S., Spiegelman, B. M., & Seale, P. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.09.007 · Cited by 1,001
Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice
Le Roy, T., Llopis, M., Lepage, P., Bruneau, A., Rabot, S., Bevilacqua, C., Martin, P., Philippe, C., Walker, F., Bado, A., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303816 · Cited by 1,001
Grundy, S. M. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.10.004 · Cited by 882
Unger, R. H. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104057 · Cited by 875
Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace
Baffy, G., Brunt, E. M., & Caldwell, S. H. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.027 · Cited by 858
Ceramides in insulin resistance and lipotoxicity
SUMMERS, S. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2005.11.002 · Cited by 848
REGULATION OF CERAMIDE PRODUCTION AND APOPTOSIS
Kolesnick, R. N., & Krönke, M. (1998) · Annual Review of Physiology · doi:10.1146/annurev.physiol.60.1.643 · Cited by 803
Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3760 · Cited by 738
Li, F., Jiang, C., Krausz, K. W., Li, Y., Albert, I., Hao, H., Fabre, K. M., Mitchell, J. B., Patterson, A. D., & Gonzalez, F. J. (2013) · Nature Communications · doi:10.1038/ncomms3384 · Cited by 705
Self-citationDel Chierico, F., Nobili, V., Vernocchi, P., Russo, A., De Stefanis, C., Gnani, D., Furlanello, C., Zandonà, A., Paci, P., Capuani, G., et al. (2017) · Hepatology · doi:10.1002/hep.28572 · Cited by 696
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76738 · Cited by 693
Self-citationTurpin, S. M., Nicholls, H. T., Willmes, D. M., Mourier, A., Brodesser, S., Wunderlich, C. M., Mauer, J., Xu, E., Hammerschmidt, P., Brönneke, H. S., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.002 · Cited by 691
Raman, M., Ahmed, I., Gillevet, P. M., Probert, C. S., Ratcliffe, N. M., Smith, S., Greenwood, R., Sikaroodi, M., Lam, V., Crotty, P., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.02.015 · Cited by 672
Integrated physiology and systems biology of PPARα
Kersten, S. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.02.002 · Cited by 670
Ceramide Content Is Increased in Skeletal Muscle From Obese Insulin-Resistant Humans
Adams, J. M., Pratipanawatr, T., Berria, R., Wang, E., DeFronzo, R. A., Sullards, M. C., & Mandarino, L. J. (2004) · Diabetes · doi:10.2337/diabetes.53.1.25 · Cited by 668
Enterohepatic bile salt transporters in normal physiology and liver disease
Kullak-ublick, G. A., Stieger, B., & Meier, P. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.06.005 · Cited by 658
Ceramides – Lipotoxic Inducers of Metabolic Disorders
Chaurasia, B., & Summers, S. A. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.07.006 · Cited by 616
Spencer, M. D., Hamp, T. J., Reid, R. W., Fischer, L. M., Zeisel, S. H., & Fodor, A. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.049 · Cited by 593
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine
Kim, I., Ahn, S.-H., Inagaki, T., Choi, M., Ito, S., Guo, G. L., Kliewer, S. A., & Gonzalez, F. J. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700330-jlr200 · Cited by 592
Self-citationIntestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K. W., Shi, J., Brocker, C. N., Desai, D., Amin, S. G., Bisson, W. H., et al. (2015) · Nature Communications · doi:10.1038/ncomms10166 · Cited by 559
Self-citationNonalcoholic Fatty Liver Disease in Lean Individuals in the United States
Younossi, Z. M., Stepanova, M., Negro, F., Hallaji, S., Younossi, Y., Lam, B., & Srishord, M. (2012) · Medicine · doi:10.1097/md.0b013e3182779d49 · Cited by 559
Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?
Bhatia, L. S., Curzen, N. P., Calder, P. C., & Byrne, C. D. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr453 · Cited by 496
Yang, F., Huang, X., Yi, T., Yen, Y., Moore, D. D., & Huang, W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1078 · Cited by 488
Microbiota-induced obesity requires farnesoid X receptor
Parséus, A., Sommer, N., Sommer, F., Caesar, R., Molinaro, A., Ståhlman, M., Greiner, T. U., Perkins, R., & Bäckhed, F. (2017) · Gut · doi:10.1136/gutjnl-2015-310283 · Cited by 474
Gene expression in human NAFLD
Greco, D., Kotronen, A., Westerbacka, J., Puig, O., Arkkila, P., Kiviluoto, T., Laitinen, S., Kolak, M., Fisher, R. M., Hamsten, A., et al. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00074.2008 · Cited by 427
Bile Acids as Hormones: The FXR-FGF15/19 Pathway
Kliewer, S. A., & Mangelsdorf, D. J. (2015) · Digestive Diseases · doi:10.1159/000371670 · Cited by 424
Cipriani, S., Mencarelli, A., Palladino, G., & Fiorucci, S. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m001602 · Cited by 416
Song, K., Li, T., Owsley, E., Strom, S., & Chiang, J. Y. L. (2009) · Hepatology · doi:10.1002/hep.22627 · Cited by 414
Microbiota depletion promotes browning of white adipose tissue and reduces obesity
Suárez-Zamorano, N., Fabbiano, S., Chevalier, C., Stojanović, O., Colin, D. J., Stevanović, A., Veyrat-Durebex, C., Tarallo, V., Rigo, D., Germain, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3994 · Cited by 403
Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells
Trabelsi, M.-S., Daoudi, M., Prawitt, J., Ducastel, S., Touche, V., Sayin, S. I., Perino, A., Brighton, C. A., Sebti, Y., Kluza, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms8629 · Cited by 400
Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal
Alkhouri, N., Dixon, L. J., & Feldstein, A. E. (2009) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.09.32 · Cited by 399
Seol, W. (1995) · Molecular Endocrinology · doi:10.1210/me.9.1.72 · Cited by 393
A Chemical, Genetic, and Structural Analysis of the Nuclear Bile Acid Receptor FXR
Downes, M., Verdecia, M. A., Roecker, A. J., Hughes, R., Hogenesch, J. B., Kast-Woelbern, H. R., Bowman, M. E., Ferrer, J.-L., Anisfeld, A. M., Edwards, P. A., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00104-7 · Cited by 390
Ceramide Channels Increase the Permeability of the Mitochondrial Outer Membrane to Small Proteins
Siskind, L. J., Kolesnick, R. N., & Colombini, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200754200 · Cited by 389
FXR signaling in the enterohepatic system
Matsubara, T., Li, F., & Gonzalez, F. J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.05.004 · Cited by 381
Self-citationMetabolic and metagenomic outcomes from early-life pulsed antibiotic treatment
Nobel, Y. R., Cox, L. M., Kirigin, F. F., Bokulich, N. A., Yamanishi, S., Teitler, I., Chung, J., Sohn, J., Barber, C. M., Goldfarb, D. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms8486 · Cited by 377
Biomarkers of NAFLD progression: a lipidomics approach to an epidemic
Gorden, D. L., Myers, D. S., Ivanova, P. T., Fahy, E., Maurya, M. R., Gupta, S., Min, J., Spann, N. J., McDonald, J. G., Kelly, S. L., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p056002 · Cited by 372
Xia, J. Y., Holland, W. L., Kusminski, C. M., Sun, K., Sharma, A. X., Pearson, M. J., Sifuentes, A. J., McDonald, J. G., Gordillo, R., & Scherer, P. E. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.007 · Cited by 348
Reijnders, D., Goossens, G. H., Hermes, G. D. A., Neis, E. P. J. G., van der Beek, C. M., Most, J., Holst, J. J., Lenaerts, K., Kootte, R. S., Nieuwdorp, M., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.016 · Cited by 348
Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease
Michail, S., Lin, M., Frey, M. R., Fanter, R., Paliy, O., Hilbush, B., & Reo, N. V. (2015) · FEMS Microbiology Ecology · doi:10.1093/femsec/fiu002 · Cited by 336
Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes
Claus, S. P., Tsang, T. M., Wang, Y., Cloarec, O., Skordi, E., Martin, F., Rezzi, S., Ross, A., Kochhar, S., Holmes, E., et al. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.56 · Cited by 334
Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity
Prawitt, J., Abdelkarim, M., Stroeve, J. H. M., Popescu, I., Duez, H., Velagapudi, V. R., Dumont, J., Bouchaert, E., van Dijk, T. H., Lucas, A., et al. (2011) · Diabetes · doi:10.2337/db11-0030 · Cited by 326
Self-citationNon-alcoholic fatty liver disease
Sattar, N., Forrest, E., & Preiss, D. (2014) · BMJ · doi:10.1136/bmj.g4596 · Cited by 325
The enterohepatic circulation of bile acids in mammals: form and functions
Hofmann, A. (2009) · Frontiers in Bioscience · doi:10.2741/3399 · Cited by 322
Mueller, M., Thorell, A., Claudel, T., Jha, P., Koefeler, H., Lackner, C., Hoesel, B., Fauler, G., Stojakovic, T., Einarsson, C., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.034 · Cited by 312
Transcriptional Control of Hepatic Lipid Metabolism by SREBP and ChREBP
Xu, X., So, J.-S., Park, J.-G., & Lee, A.-H. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358523 · Cited by 308
The gut microbiota and metabolic disease: current understanding and future perspectives
Arora, T., & Bäckhed, F. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12508 · Cited by 303
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
Porez, G., Prawitt, J., Gross, B., & Staels, B. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r024794 · Cited by 286
Screening of Lactic Acid Bacteria for Bile Salt Hydrolase Activity
Tanaka, H., Doesburg, K., Iwasaki, T., & Mierau, I. (1999) · Journal of Dairy Science · doi:10.3168/jds.s0022-0302(99)75506-2 · Cited by 283
Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice
De Minicis, S., Rychlicki, C., Agostinelli, L., Saccomanno, S., Candelaresi, C., Trozzi, L., Mingarelli, E., Facinelli, B., Magi, G., Palmieri, C., et al. (2014) · Hepatology · doi:10.1002/hep.26695 · Cited by 279
Detoxification of Lithocholic Acid, A Toxic Bile Acid: Relevance to Drug Hepatotoxicity
Hofmann, A. F. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-200033475 · Cited by 268
Top-Down Systems Biology Modeling of Host Metabotype−Microbiome Associations in Obese Rodents
Waldram, A., Holmes, E., Wang, Y., Rantalainen, M., Wilson, I. D., Tuohy, K. M., McCartney, A. L., Gibson, G. R., & Nicholson, J. K. (2009) · Journal of Proteome Research · doi:10.1021/pr8009885 · Cited by 264
Role of the Gut Microbiome in Obesity and Diabetes Mellitus
Barlow, G. M., Yu, A., & Mathur, R. (2015) · Nutrition in Clinical Practice · doi:10.1177/0884533615609896 · Cited by 262
Role of nuclear receptor SHP in metabolism and cancer
Zhang, Y., Hagedorn, C. H., & Wang, L. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.10.006 · Cited by 235
Copple, B. L., & Li, T. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.12.007 · Cited by 235
Brown Fat and Browning for the Treatment of Obesity and Related Metabolic Disorders
Kim, S. H., & Plutzky, J. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.1.12 · Cited by 234
Role of the Intestinal Bile Acid Transporters in Bile Acid and Drug Disposition
Dawson, P. A. (2011) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-14541-4_4 · Cited by 227
Maran, R. R. M., Thomas, A., Roth, M., Sheng, Z., Esterly, N., Pinson, D., Gao, X., Zhang, Y., Ganapathy, V., Gonzalez, F. J., et al. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.145409 · Cited by 220
Self-citationIncreased skeletal muscle ceramide level in men at risk of developing type 2 diabetes
Straczkowski, M., Kowalska, I., Baranowski, M., Nikolajuk, A., Otziomek, E., Zabielski, P., Adamska, A., Blachnio, A., Gorski, J., & Gorska, M. (2007) · Diabetologia · doi:10.1007/s00125-007-0781-2 · Cited by 218
Gallego-Escuredo, J. M., Gómez-Ambrosi, J., Catalan, V, Domingo, P., Giralt, M., Frühbeck, G., & Villarroya, F. (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.76 · Cited by 209
Role of ceramide in diabetes mellitus: evidence and mechanisms
Galadari, S., Rahman, A., Pallichankandy, S., Galadari, A., & Thayyullathil, F. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-98 · Cited by 195
Mahana, D., Trent, C. M., Kurtz, Z. D., Bokulich, N. A., Battaglia, T., Chung, J., Müller, C. L., Li, H., Bonneau, R. A., & Blaser, M. J. (2016) · Genome Medicine · doi:10.1186/s13073-016-0297-9 · Cited by 190
Gangarapu, V., İnce, A. T., Baysal, B., Kayar, Y., Klç, U., Gök, Ö., Uysal, Ö., & Şentürk, H. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000348 · Cited by 164
Roles of ceramide and sphingolipids in pancreatic β-cell function and dysfunction
Boslem, E., Meikle, P. J., & Biden, T. J. (2012) · Islets · doi:10.4161/isl.20102 · Cited by 158
Elshaghabee, F. M. F., Bockelmann, W., Meske, D., de Vrese, M., Walte, H.-G., Schrezenmeir, J., & Heller, K. J. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00047 · Cited by 151
Donepudi, A. C., Boehme, S., Li, F., & Chiang, J. Y. L. (2016) · Hepatology · doi:10.1002/hep.28707 · Cited by 151
Zweers, S. J. L. B., Booij, K. A. C., Komuta, M., Roskams, T., Gouma, D. J., Jansen, P. L. M., & Schaap, F. G. (2011) · Hepatology · doi:10.1002/hep.24702 · Cited by 141
Vaquero, J., Monte, M. J., Domínguez, M., Muntané, J., & Marı́n, J. J. G. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.022 · Cited by 134
The Gut Microbiota and Nonalcoholic Fatty Liver Disease
Quigley, E., & Monsour, H. (2015) · Seminars in liver disease (Print) · doi:10.1055/s-0035-1562946 · Cited by 123
Degirolamo, C., Modica, S., Vacca, M., Di Tullio, G., Morgano, A., D'Orazio, A., Kannisto, K., Parini, P., & Moschetta, A. (2015) · Hepatology · doi:10.1002/hep.27274 · Cited by 121
Su, H., Ma, C., Liu, J., Li, N., Gao, M., Huang, A., Wang, X., Huang, W., & Huang, X. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00439.2011 · Cited by 117
Nuclear Receptor Control of Enterohepatic Circulation
Gonzalez, F. J. (2012) · Comprehensive physiology · doi:10.1002/cphy.c120007 · Cited by 110
Self-citationMicrobial transformation of quinoline by a Pseudomonas sp
Shukla, O. P. (1986) · Applied and Environmental Microbiology · doi:10.1128/aem.51.6.1332-1342.1986 · Cited by 110
Lithocholic acid disrupts phospholipid and sphingolipid homeostasis leading to cholestasis in mice
Matsubara, T., Tanaka, N., Patterson, A. D., Cho, J., Krausz, K. W., & Gonzalez, F. J. (2011) · Hepatology · doi:10.1002/hep.24193 · Cited by 98
Self-citationCeramide channels and mitochondrial outer membrane permeability
Colombini, M. (2016) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-016-9646-z · Cited by 98
FXR an emerging therapeutic target for the treatment of atherosclerosis
Mencarelli, A., & Fiorucci, S. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00997.x · Cited by 97
A low molecular weight antioxidant decreases weight and lowers tumor incidence
Mitchell, J. B., Xavier, S., DeLuca, A. M., Sowers, A. L., Cook, J. A., Krishna, M. C., Hahn, S. M., & Russo, A. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)01193-0 · Cited by 94
Ceramide formation as a target in beta-cell survival and function
Lang, F. J. W., Ullrich, S., & Gulbins, E. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.588209 · Cited by 92
Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes
Duan, H., Ning, M., Zou, Q., Ye, Y., Feng, Y., Zhang, L., Leng, Y., & Shen, J. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm500829b · Cited by 90
Chen, J. Y., Levy-Wilson, B., Goodart, S. A., & Cooper, A. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205117200 · Cited by 87
Stepanov, V., Stankov, K., & Mikov, M. (2013) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2013.802805 · Cited by 85
Wójcik, M., Januś, D., Doleżal-Ołtarzewska, K., Kalicka-Kasperczyk, A., Popławska, K., Drożdż, D., Sztefko, K., & Starzyk, J. (2012) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2012-0253 · Cited by 81
Zhen, Y., Krausz, K. W., Chen, C., Idle, J. R., & Gonzalez, F. J. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0150 · Cited by 76
Self-citationHepatocyte nuclear factor 4α regulation of bile acid and drug metabolism
Chiang, J. Y. L. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802707342 · Cited by 76
Sakakura, H., Suzuki, M., Kimura, N., Takeda, H., Nagata, S., & Maëda, M. (1993) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/0378-4347(93)80087-k · Cited by 73
Miyata, M., Takamatsu, Y., Kuribayashi, H., & Yamazoe, Y. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160093 · Cited by 72
Microbial Determinants of Biochemical Individuality and Their Impact on Toxicology and Pharmacology
Patterson, A. D., & Turnbaugh, P. J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.002 · Cited by 68
Self-citationKuribayashi, H., Miyata, M., Yamakawa, H., Yoshinari, K., & Yamazoe, Y. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.048 · Cited by 68
Promrat, K., Longato, L., Wands, J. R., & de la Monte, S. M. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00815.x · Cited by 66
Immune Responses to Intestinal Microbes in Inflammatory Bowel Diseases
Hansen, J. J. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0562-9 · Cited by 61
Cancer chemoprevention by the antioxidant tempol acts partially via the p53 tumor suppressor
Erker, L. R., Schubert, R., Yakushiji, H., Barlow, C., Larson, D., Mitchell, J. B., & Wynshaw-Boris, A. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi181 · Cited by 60
Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases
Stanimirov, B., Stankov, K., & Mikov, M. (2015) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(14)60307-6 · Cited by 59
Human Urinary Metabolomic Profile of PPARα Induced Fatty Acid β-Oxidation
Patterson, A. D., Slanař, O., Krausz, K. W., Li, F., Höfer, C. C., Perlík, F., Gonzalez, F. J., & Idle, J. R. (2009) · Journal of Proteome Research · doi:10.1021/pr9004103 · Cited by 57
Self-citationTreatment of Non-Alcoholic Fatty Liver Disease
Dyson, J. K., & Day, C. (2014) · Digestive Diseases · doi:10.1159/000360511 · Cited by 54
Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis
Silveira, M. G., & Lindor, K. D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.873404 · Cited by 53
Gut microbiota-associated bile acid deconjugation accelerates hepatic steatosis in ob/ob mice
Park, M.-Y., Kim, S. J., Ko, E., Ahn, S., Seo, H., & Sung, M. (2016) · Journal of Applied Microbiology · doi:10.1111/jam.13158 · Cited by 53
Gut Microbiota and Clinical Disease: Obesity and Nonalcoholic Fatty Liver Disease
Park, J. S., Seo, J., & Youn, H. (2013) · Pediatric Gastroenterology Hepatology & Nutrition · doi:10.5223/pghn.2013.16.1.22 · Cited by 52
Ursodeoxycholic Acid Amides As Novel Glucocorticoid Receptor Modulators
Sharma, R., Prichard, D. O., Májer, F., Byrne, A.-M., Kelleher, D. P., Long, A., & Gilmer, J. F. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100860s · Cited by 38
Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease
Aqel, B. A., & DiBaise, J. K. (2015) · Nutrition in Clinical Practice · doi:10.1177/0884533615605811 · Cited by 37
Bacterial metabolites directly modulate farnesoid X receptor activity
Zhang, X., Osaka, T., & Tsuneda, S. (2015) · Nutrition & Metabolism · doi:10.1186/s12986-015-0045-y · Cited by 34
Shukla, O. P. (1989) · PubMed · Cited by 33
Li, F., Pang, X., Krausz, K. W., Jiang, C., Chen, C., Cook, J. A., Krishna, M. C., Mitchell, J. B., Gonzalez, F. J., & Patterson, A. D. (2013) · Journal of Proteome Research · doi:10.1021/pr301023x · Cited by 31
Self-citationInhibition of farnesoid X receptor signaling shows beneficial effects in human obesity
Gonzalez, F. J., Jiang, C., Bisson, W. H., & Patterson, A. D. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.043 · Cited by 31
Self-citationIrinotecan (CPT-11)-induced elevation of bile acids potentiates suppression of IL-10 expression
Fang, Z., Zhang, D., Cao, Y., Xie, C., Lü, D., Sun, D., Tanaka, N., Jiang, C., Chen, Q., Chen, Y., et al. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.12.003 · Cited by 31
Self-citationNovel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease
Yu, D. D., Andrali, S. S., Li, H., Lin, M., Huang, W., & FORMAN, B. M. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.06.039 · Cited by 31
Sakakura, H., Kimura, N., Takeda, H., Komatsu, H., Ishizaki, K., & Nagata, S. (1998) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(98)00342-9 · Cited by 30
Cheng, Q., Inaba, Y., Lu, P., Xu, M., He, J., Zhao, Y., Guo, G. L., Kuruba, R., de la Vega, R., Evans, R. G., et al. (2015) · Molecular Endocrinology · doi:10.1210/me.2014-1337 · Cited by 22
Use of Farnesoid X Receptor Agonists to Treat Nonalcoholic Fatty Liver Disease
Sanyal, A. J. (2015) · Digestive Diseases · doi:10.1159/000371698 · Cited by 20
Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases
Bojan, Stanimirov, Karmen, et al. (2015) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 17
Maliqueo, M. A., Echiburú, B., & Cavada, G. (2016) · Cited by 10
Insulin resistance and “Lipotoxic Liver Diseases”
Ahammed, S. K. M., & Chowdhury, A. (2013) · Tropical Gastroenterology · doi:10.7869/tg.2012.82 · Cited by 3
Cited by
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin
Sun, L., Xie, C., Wang, G., Wu, Y., Wu, Q., Wang, X., Liu, J., Deng, Y., Xia, J., Chen, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0222-4 · Cited by 1,011
Self-citationGut-liver axis: Pathophysiological concepts and clinical implications
Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.017 · Cited by 843
Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy
Chiang, J. Y. L., & Ferrell, J. M. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00223.2019 · Cited by 580
Bile Acid Metabolism in Liver Pathobiology
Chiang, J. Y. L., & Ferrell, J. M. (2018) · Gene Expression · doi:10.3727/105221618x15156018385515 · Cited by 546
The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)
Safari, Z., & Gérard, P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03011-w · Cited by 502
Metadata
- Authors
- Gonzalez, F. J., Jiang, C., & Patterson, A. D.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 151
- Issue
- 5
- Pages
- 845-859
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2519008943
- Cited by
- 372
- References
- 139
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.